AG Kokott: GSK pay-for-delay agreements “may be” abusive
GlaxoSmithKline may have abused its dominant position when it signed pay-for-delay agreements with three generic drugmakers, an advocate general to the European Court of Justice has said.
To read more
Subscribe to Global Competition Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now